Extended Data Fig. 3: Sample flow for the concordance study comparing the bTMB CTA and F1L CDx assay for bTMB ≥10 and for bTMB ≥16. | Nature Medicine

Extended Data Fig. 3: Sample flow for the concordance study comparing the bTMB CTA and F1L CDx assay for bTMB ≥10 and for bTMB ≥16.

From: Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial

Extended Data Fig. 3

Sample flow for the concordance study comparing the bTMB CTA and F1L CDx assay for (A) bTMB ≥10 and for (B) bTMB ≥16. The bTMB ≥16 samples are a subset of the bTMB ≥10 samples. BEP, biomarker-evaluable population; bTMB, blood-based tumor mutational burden; CTA, clinical trial assay; F1L CDx, FoundationOne Liquid Companion Diagnostic. aExcludes patients who withdrew consent or with unavailable samples. b6 samples failed quality check. c3 samples failed quality check.

Back to article page